Fig. 2From: Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitorsOverview on agents targeting different parts of proteasome-mediated degradation pathway, including E1, E2, E3, and the proteasome itselfBack to article page